Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (294)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (294)
Apply filters
Showing 251 to 294 of 294
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Spesolimab for treating acute generalised pustular psoriasis [ID3963]
Technology appraisal guidance
TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Technology appraisal guidance
9 July 2024
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
Technology appraisal guidance
19 June 2024
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
TBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]
Technology appraisal guidance
14 August 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Tenecteplase for treating acute ischaemic stroke [ID6306]
Technology appraisal guidance
TBC
Third molars (impacted) - prophylactic removal [ID898]
Technology appraisal guidance
TBC
Tirzepatide for managing overweight and obesity [ID6179]
Technology appraisal guidance
19 June 2024
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]
Technology appraisal guidance
TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]
Technology appraisal guidance
TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]
Technology appraisal guidance
TBC
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]
Technology appraisal guidance
24 July 2024
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Technology appraisal guidance
TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Technology appraisal guidance
25 September 2024
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]
Technology appraisal guidance
TBC
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350
Technology appraisal guidance
TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Technology appraisal guidance
TBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]
Technology appraisal guidance
20 November 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Technology appraisal guidance
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
Technology appraisal guidance
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Technology appraisal guidance
TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Technology appraisal guidance
TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Technology appraisal guidance
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Technology appraisal guidance
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Technology appraisal guidance
TBC
Vibegron for treating symptoms of overactive bladder ID6300
Technology appraisal guidance
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Voxelotor for treating sickle cell disease [ID1403]
Technology appraisal guidance
12 June 2024
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
Technology appraisal guidance
17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
Technology appraisal guidance
7 August 2024
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]
Technology appraisal guidance
23 October 2024
Previous page
1
4
5
Current page
6
Page
6
of
6
Results per page
10
25
50
All
Back to top